Spirulina and Notch Signalling: Jagged/DLL Ligands, γ-Secretase, NICD, and Intestinal Stem Cells

The Notch Receptor Family: Structure and Activation Logic

Mammals express four Notch receptors—Notch1 through Notch4—each of which is a single-pass type-I transmembrane protein processed constitutively in the Golgi by furin into a heterodimer of a large extracellular domain (ECD, containing 29–36 EGF-like repeats) non-covalently associated with a shorter transmembrane and intracellular domain fragment. This furin-processed heterodimer is the form that reaches the cell surface. The EGF repeats mediate ligand binding; EGF repeats 11 and 12 are the primary contact surfaces for both Jagged and Delta-like ligands.

Notch signalling is strictly contact-dependent: ligands are also transmembrane proteins expressed on adjacent cells, and the receptor–ligand interaction requires the mechanical force generated by ligand endocytosis in the signal-sending cell to expose the proteolytic sites on the receptor in the signal-receiving cell. This mechanical unfolding is not merely incidental—it is essential for productive signalling, which is why soluble ligand ectodomains typically act as antagonists rather than agonists.

Jagged1/2 and DLL1/3/4: Distinct Ligand Biology

The five canonical Notch ligands divide into two families with distinct expression patterns and signalling outcomes. The Delta-like ligands (DLL1, DLL3, DLL4) lack the CR (cysteine-rich) domain found in Jagged proteins and generally produce stronger Notch activation. DLL4 is the primary ligand for Notch1 in vascular endothelium, where DLL4-Notch1 signalling controls tip-versus-stalk cell specification during angiogenesis—DLL4 expressed by the tip cell activates Notch1 in adjacent stalk cells, suppressing their tip-cell identity and restraining vessel branching. DLL1 and DLL3 are important in somitogenesis and neurogenesis. In the intestinal crypt, DLL1 and DLL4 on Paneth cells at the crypt base activate Notch1 on adjacent Lgr5+ stem cells, maintaining stem cell identity and proliferative capacity.

The Jagged ligands (JAG1 and JAG2) tend to produce weaker or qualitatively different Notch activation, partly because Jagged-Notch signalling recruits different co-regulatory complexes and may preferentially activate Notch2 and Notch3 over Notch1. JAG1 is expressed on biliary epithelium (mutations causing Alagille syndrome) and in vascular smooth muscle. JAG2 participates in T-cell differentiation in the thymus. The qualitative differences between Jagged and DLL outputs likely reflect differences in NICD conformational states and duration of nuclear residency rather than intrinsically different signalling components.

ADAM10 and γ-Secretase: Sequential S2/S3 Proteolysis

Upon ligand binding and mechanical unfolding of the Notch negative regulatory region (NRR), the metalloprotease ADAM10 (a disintegrin and metalloproteinase 10) performs the first ectodomain shedding event, the S2 cleavage, at a site just outside the transmembrane domain. This generates a membrane-tethered fragment (NEXT, Notch extracellular truncation) that becomes the substrate for the γ-secretase complex. γ-Secretase is a multi-protein intramembrane protease whose catalytic subunit is presenilin 1 or 2 (PSEN1/PSEN2), assembled with nicastrin, APH-1, and PEN-2 into a stable complex. It cleaves NEXT at the S3 site within the transmembrane helix, releasing the Notch intracellular domain (NICD) into the cytoplasm. The same γ-secretase complex also processes amyloid precursor protein (APP) into Aβ peptides, which is why γ-secretase inhibitors (GSIs) developed as Alzheimer's drugs produced Notch-related intestinal side effects in clinical trials—nausea, diarrhoea, and goblet cell metaplasia consistent with Notch loss-of-function in the gut.

NICD Nuclear Translocation and the CSL/RBPJ Transcriptional Complex

NICD contains an RBJP-association module (RAM domain) and ankyrin repeats that together mediate its interaction with CSL (CBF1/RBPJ in vertebrates, named for the orthologues in C. elegans, Drosophila, and mammals). In the absence of NICD, CSL/RBPJ recruits a co-repressor complex including SHARP, SMRT, and HDAC1/3 to Notch target gene promoters, maintaining transcriptional repression. NICD displaces this co-repressor complex, recruits MAML1/2/3 (Mastermind-like) as a scaffold, and in turn recruits p300/CBP, converting CSL into a transcriptional activator. The result is rapid induction of the primary target genes HES1 (hairy and enhancer of split 1) and HEY1 (hairy/enhancer of split-related with YRPW motif 1)—both basic helix-loop-helix transcriptional repressors. HES1 represses Atonal homologue 1 (ATOH1/Math1), the master regulator of secretory cell fate; high Notch activity therefore drives intestinal progenitors toward the absorptive enterocyte lineage, while low Notch activity (or pharmacological Notch inhibition) shifts the balance toward goblet cell, Paneth cell, and enteroendocrine fates.

NICD stability is regulated by a dedicated E3 ligase complex: FBXW7 (CDC4/SEL-10) in complex with SCF ubiquitinates NICD at the PEST domain, targeting it for proteasomal degradation. Loss-of-function FBXW7 mutations, found in T-cell leukaemia and various solid tumours, lead to NICD accumulation and constitutive Notch signalling—a pathological mirror of the physiological nuclear residency control.

Intestinal Stem Cells, Lgr5+ Cells, and Crypt Homeostasis

The intestinal crypt bottom harbours two interdigitating cell types: Lgr5+ crypt base columnar (CBC) stem cells and Paneth cells. Paneth cells provide the stem cell niche by secreting Wnt3, EGF, and Notch ligands DLL1 and DLL4, maintaining the CBC stem cells in a proliferative, undifferentiated state. Lgr5+ cells with active Notch1 signalling (NICD nuclear) self-renew and produce transit-amplifying progenitors; those that lose Notch signalling as they migrate up the crypt differentiate into secretory lineages via ATOH1 upregulation. This binary readout—Notch-high is absorptive, Notch-low is secretory—is supported by elegant clonal analysis and pharmacological studies. Inflammatory bowel disease disrupts this patterning: elevated TNF-α and IL-1β suppress DLL1/DLL4 expression on Paneth cells, reduce Notch signalling in CBC stem cells, and drive expansion of goblet cells and entero- endocrine cells at the expense of absorptive enterocytes in a context-dependent, tissue-remodelling response to injury.

NF-κB/Notch Cross-Talk and Spirulina's Intersection

The transcriptional cross-talk between NF-κB and Notch is bidirectional and context-dependent. In the intestinal epithelium, NF-κB can directly induce HES1 transcription through κB sites in the HES1 promoter, meaning that inflammatory NF-κB activation in colonocytes mimics some aspects of Notch signalling at the transcriptional level and may improperly maintain an absorptive-fate programme in contexts where secretory cell renewal is needed. Additionally, NICD has been shown to interact with IκBα, sequestering it and promoting NF-κB activity in some cell types—a positive-feedback loop relevant to T-cell leukaemia and hepato- cellular carcinoma where both pathways are co-activated. Conversely, in macrophages, Notch1 activation promotes inflammatory gene expression in concert with NF-κB at shared target loci.

Phycocyanin's IKKβ inhibition suppresses NF-κB-driven HES1 induction in colonocytes—a potentially protective effect when aberrant NF-κB is maintaining tumour stem-cell-like proliferation through ectopic HES1 expression, as seen in colorectal cancer models. More broadly, by reducing the inflammatory milieu (lower TNF-α, lower IL-1β) in the intestinal lamina propria, spirulina's anti- inflammatory effects help preserve Paneth cell DLL1/DLL4 expression and thereby support normal Lgr5+ stem cell Notch signalling rather than the dysregulated inflammatory pseudo-Notch state. This is a homeostatic rather than a pharmacological intervention—preserving the conditions for normal crypt architecture rather than acutely modulating NICD levels directly.

Practical Takeaway

Notch signalling in the intestine is not simply a target to activate or suppress; it is a spatial patterning system that needs to be maintained within tight parameters. Too much Notch (as in Notch-activating mutations or FBXW7 loss) drives absorptive expansion and suppresses the mucus-secreting goblet cells whose absence compromises barrier function. Too little Notch (as with γ-secretase inhibitor treatment or sustained inflammation suppressing Paneth cell DLL expression) drives goblet cell metaplasia and impairs stem cell renewal. Spirulina's contributions here are indirect but coherent: reducing the NF-κB-driven HES1 induction that substitutes for proper Notch signalling, preserving the Paneth cell niche through anti-inflammatory effects, and supporting the autophagy and proteostasis that Lgr5+ stem cells depend on. For people with inflammatory gut pathology where crypt architecture is disrupted, this represents a mechanistically rational background upon which conventional treatment operates.